论文部分内容阅读
目的:探讨血清sICAM-1,sVCAM-1水平测定在非小细胞肺癌中的临床意义。方法:应用ELISA法测定43例非小细胞肺癌患者(其中14例为化疗后患者)血清sICAM-1、sVCAM-1的浓度,并与正常人比较。结果:Ⅰ+Ⅱ期、Ⅲ+Ⅳ期肺癌患者sICAM-1的浓度分别为370.65±78.63ng/ml、550.88±343.31ng/ml均明显高于正常组(P<0.01),且Ⅲ+Ⅳ期患者的sICAMV-1与Ⅰ+Ⅱ期比较具有显著性差异(P<0.05),Ⅰ+Ⅱ期、Ⅲ+Ⅳ期肺癌患者sVCAM-1的浓度分别为543.92±142.37ng/ml、885.12±892.12ng/ml均明显高于正常组(P<0.01),且二者之间也存在差异(P<0.05)。14例化疗后的患者sICAM-1、sVCAM-1分别为351.78±161.80ng/ml、418.64±251.64ng/ml均明显低于化疗前(P<0.05,P<0.01)。结论:血清sICAM-1,sVCAM-1水平与肺癌的病情发展相关,并有可能作为肺癌化疗评价疗效的血清学指标之一。
Objective: To investigate the clinical significance of serum sICAM-1 and sVCAM-1 levels in non-small cell lung cancer. Methods: Serum levels of sICAM-1 and sVCAM-1 were measured in 43 patients with NSCLC (including 14 patients after chemotherapy) by ELISA, and compared with normal subjects. Results: The levels of sICAM-1 in Ⅰ + Ⅱ and Ⅲ + Ⅳ lung cancer patients were 370.65 ± 78.63ng / ml and 550.88 ± 343.31ng / ml, respectively, which were significantly higher than those in normal group (P <0.01) The levels of sVCAM-1 in stage Ⅰ + Ⅱ and stage Ⅲ + Ⅳ lung cancer patients were 543.92 ± 142.37ng / ml and 885.12 ± 892.12ng, respectively, compared with those in stage Ⅰ + Ⅱ (P <0.05) / ml were significantly higher than the normal group (P <0.01), and there was also a difference between the two (P <0.05). The sICAM-1 and sVCAM-1 levels in the 14 patients after chemotherapy were 351.78 ± 161.80ng / ml and 418.64 ± 251.64ng / ml, respectively, which were significantly lower than those before chemotherapy (P <0.05, P <0.01). Conclusion: The serum levels of sICAM-1 and sVCAM-1 are correlated with the progression of lung cancer and may be used as one of the serological markers for evaluating the efficacy of chemotherapy for lung cancer.